13Feb 2021
Development of Novel Antibody-Camptothecin Conjugates

Development of Novel Antibody-Camptothecin Conjugates

We have developed a highly active and well-tolerated camptothecin (CPT) drug-linker designed for antibody-mediated drug delivery in which the lead molecule consists of a 7-aminomethyl-10,11-methylenedioxy CPT (CPT1) derivative payload attached to a novel hydrophilic protease-cleavable valine–lysine–glycine tripeptide linker.

  • #oncology

Like

Save

Share